1
|
Dougé A, Vituret C, Carraro V, Parry L, Coudy-Gandilhon C, Lemal R, Combaret L, Maurin AC, Averous J, Jousse C, Bay JO, Verrelle P, Fafournoux P, Bruhat A, Rouzaire P. Temporal regulation of transgene expression controlled by amino acid availability in human T cells. HLA 2024; 103:e15252. [PMID: 37848366 DOI: 10.1111/tan.15252] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2023] [Revised: 07/12/2023] [Accepted: 09/28/2023] [Indexed: 10/19/2023]
Abstract
T cell therapy strategies, from allogeneic stem cell transplantation toward genetically-modified T cells infusion, develop powerful anti-tumor effects but are often accompanied by side effects and their efficacy remains sometimes to be improved. It therefore appears important to provide a flexible and easily reversible gene expression regulation system to control T cells activity. We developed a gene expression regulation technology that exploits the physiological GCN2-ATF4 pathway's ability to induce gene expression in T cells in response to one essential amino acid deficiency. We first demonstrated the functionality of NUTRIREG in human T cells by transient expression of reporter genes. We then validated that NUTRIREG can be used in human T cells to transiently express a therapeutic gene such as IL-10. Overall, our results represent a solid basis for the promising use of NUTRIREG to regulate transgene expression in human T cells in a reversible way, and more generally for numerous preventive or curative therapeutic possibilities in cellular immunotherapy strategies.
Collapse
Affiliation(s)
- Aurore Dougé
- Université Clermont Auvergne, INRAE, UNH, UMR1019, Clermont-Ferrand, France
- Medical Oncology Department, CHU Gabriel Montpied, Clermont-Ferrand, France
- EA Chelter 7453, Université Clermont Auvergne, Clermont-Ferrand, France
| | - Cyrielle Vituret
- Université Clermont Auvergne, INRAE, UNH, UMR1019, Clermont-Ferrand, France
| | - Valérie Carraro
- Université Clermont Auvergne, INRAE, UNH, UMR1019, Clermont-Ferrand, France
| | - Laurent Parry
- Université Clermont Auvergne, INRAE, UNH, UMR1019, Clermont-Ferrand, France
| | | | - Richard Lemal
- EA Chelter 7453, Université Clermont Auvergne, Clermont-Ferrand, France
- Histocompatibility and Immunogenetics Department, CHU Gabriel Montpied, Clermont-Ferrand, France
| | - Lydie Combaret
- Université Clermont Auvergne, INRAE, UNH, UMR1019, Clermont-Ferrand, France
| | | | - Julien Averous
- Université Clermont Auvergne, INRAE, UNH, UMR1019, Clermont-Ferrand, France
| | - Céline Jousse
- Université Clermont Auvergne, INRAE, UNH, UMR1019, Clermont-Ferrand, France
| | - Jacques-Olivier Bay
- Medical Oncology Department, CHU Gabriel Montpied, Clermont-Ferrand, France
- EA Chelter 7453, Université Clermont Auvergne, Clermont-Ferrand, France
| | - Pierre Verrelle
- EA Chelter 7453, Université Clermont Auvergne, Clermont-Ferrand, France
- Radiation Oncology Department, Institut Curie, PSL Research University, Paris, France
- Institut-Curie Recherche, U1196/UMR9187, Orsay, France
| | - Pierre Fafournoux
- Université Clermont Auvergne, INRAE, UNH, UMR1019, Clermont-Ferrand, France
| | - Alain Bruhat
- Université Clermont Auvergne, INRAE, UNH, UMR1019, Clermont-Ferrand, France
| | - Paul Rouzaire
- EA Chelter 7453, Université Clermont Auvergne, Clermont-Ferrand, France
- Histocompatibility and Immunogenetics Department, CHU Gabriel Montpied, Clermont-Ferrand, France
| |
Collapse
|